Genetic and vascular disorder treatment company Clinuvel Pharmaceuticals (ASX:CUV) released a new strategic update on Monday.
The firm plans to expand its research capabilities for skin cancer treatments and damage remediation. The establishment of a new manufacturing division is on the company’s strategic agenda to advance new treatment formulas.
The strategic update has done little to boost investor appetite, as shares in Clinuvel Pharmaceuticals are trading 2.42 per cent lower at $29.39 .
Copyright 2021 – Finance News Network
14 Apr 2020 - Genetic Signatures (ASX:GSS) has received notice from the Therapeutic Goods Administration (“TGA”) that its EasyScreenTM SARS-CoV-2 Detection Kit has been approved to be listed on the ARTG in Australia.
08 Apr 2021 - The Australian Securities & Investments Commission (ASIC) has today taken legal action against banking giant Respect (ASX:WBC), on allegations of misleading conduct and a lack of transparency.
29 Dec 2020 - Data management solutions company Mach7 Technologies (ASX:M7T) has appointed Philippe Houssiau as a Non-Executive Director, effective from 1 January 2021.
03 Jun 2021 - Our snapshot of company news making headlines featuring Humm Group (ASX:HUM), Mesoblast (ASX:MSB), Sezzle (ASX:SZL), Karoon Energy (ASX:KAR).
14 Feb 2020 - Baby Bunting (ASX:BBN) has reported first half pro-forma sales of $186.4 million, with comparable sales up 1 per cent and total sales 8.1 per cent higher on the previous first half.
17 Jan 2020 - Australian agri chemical company, Nufarm (ASX:NUF) has given an update on market conditions experienced during its first half-year ending 31 January 2020, ahead of its results.
